Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 03 November 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) on Friday issued a revised version of its draft guidance on the information that must be pre-submitted in order to receive a priority review for an abbreviated new drug application (ANDA).
As part of the negotiations to reauthorize the Generic Drug User Fee Amendments (GDUFA II), FDA agreed to shorten its review of eligible priority generics by two months if sponsors submit a pre-submission facility correspondence (PFC) at least two months ahead of their ANDA submission. FDA would then use that two-month period to determine whether facility inspections are needed, and when they are, to begin inspection planning earlier in the review process.
But since drafting the original version of the guidance, the FDA Reauthorization Act was signed into law, bringing with it some changes to the information the agency can collect as part of a PFC.
According to FDA, FDARA permits the agency to "utilize the existing process for submission of ANDAs (including electronic Common Technical Document (eCTD) submission format) for the pre-submission of facility information and avoids duplicative effort by applicants that would have been required if the relevant facility information had to be submitted as identified in the original draft guidance."
Under the previous version of the guidance, FDA would have required applicants to submit their PFCs electronically via the agency's electronic submission gateway (ESG) in a non-eCTD format, whereas the revised version requires the submission to be in eCTD format.
As such, the new version of the guidance includes a table detailing the specific eCTD sections that must be included in a PFC. FDA also notes that for prior approval supplements (PAS) and ANDA amendments, applicants only need to include the eCTD sections that are relevant to those types of submissions.
Because some companies may have already been preparing PFCs in a non-eCTD format, FDA says it will allow sponsors to follow either version of the draft guidance until 6 December 2017.
Additionally, FDA says it will still consider comments submitted to the original version when finalizing the guidance, so that stakeholders do not have resubmit their comments.
It's unclear whether the revisions will ease generic drugmakers concerns about the priority ANDA program. Comments from the generic drug industry group the Association for Affordable Medicines AAM on the previous version called the program "basically inoperable" and said it would require companies to submit a "mini ANDA" ahead of their actual submission.
Generic drugmaker Teva also commented on the earlier version saying the guidance "exceeds the details included in the commitment letter."
Revised Draft Guidance, Federal Register Notice
Tags: Priority ANDAs, GDUFA II, Pre-Submission Facility Correspondence, PFC
Regulatory Focus newsletters
All the biggest regulatory news and happenings.